Analysts Set Expectations for BCRX Q1 Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) – Research analysts at Wedbush issued their Q1 2025 EPS estimates for BioCryst Pharmaceuticals in a report released on Tuesday, February 25th. Wedbush analyst L. Chico expects that the biotechnology company will post earnings per share of ($0.06) for the quarter. Wedbush has a “Outperform” rating and a $15.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals’ Q2 2025 earnings at ($0.03) EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.11 EPS, FY2025 earnings at $0.04 EPS, Q1 2026 earnings at $0.03 EPS, Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.09 EPS, Q4 2026 earnings at $0.15 EPS, FY2026 earnings at $0.35 EPS, FY2027 earnings at $0.69 EPS, FY2028 earnings at $0.87 EPS and FY2029 earnings at $1.09 EPS.

Several other analysts have also recently weighed in on BCRX. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday. Needham & Company LLC raised their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Barclays raised their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and set a $11.00 price objective (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday. Finally, JMP Securities reissued a “market outperform” rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.57.

BioCryst Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ:BCRX opened at $8.47 on Thursday. The firm’s 50 day moving average price is $8.09 and its 200 day moving average price is $7.85. The stock has a market cap of $1.75 billion, a price-to-earnings ratio of -13.89 and a beta of 1.75. BioCryst Pharmaceuticals has a fifty-two week low of $4.03 and a fifty-two week high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. The firm’s quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.28 earnings per share.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently made changes to their positions in the stock. Xponance Inc. boosted its position in shares of BioCryst Pharmaceuticals by 9.1% during the 4th quarter. Xponance Inc. now owns 14,896 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 1,242 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of BioCryst Pharmaceuticals by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,322 shares in the last quarter. Sei Investments Co. boosted its position in shares of BioCryst Pharmaceuticals by 2.8% during the 4th quarter. Sei Investments Co. now owns 57,190 shares of the biotechnology company’s stock worth $430,000 after purchasing an additional 1,537 shares in the last quarter. Captrust Financial Advisors boosted its position in shares of BioCryst Pharmaceuticals by 19.4% during the 3rd quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock worth $124,000 after purchasing an additional 2,644 shares in the last quarter. Finally, Creative Planning boosted its position in shares of BioCryst Pharmaceuticals by 5.9% during the 3rd quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock worth $375,000 after purchasing an additional 2,734 shares in the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.